What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Breast cancer
Richard D. Gelber mainly focuses on Internal medicine, Oncology, Breast cancer, Surgery and Chemotherapy.
Clinical trial, Randomized controlled trial, Trastuzumab, Hazard ratio and Cancer are the core of his Internal medicine study.
His Oncology course of study focuses on Mammary gland and Pathology.
He has researched Breast cancer in several fields, including Gynecology, Radiation therapy and Chemotherapy regimen.
His Surgery research includes themes of Acute lymphocytic leukemia and Cardiology.
His Chemotherapy research incorporates elements of Meta-analysis and Goserelin.
His most cited work include:
- Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer (4015 citations)
- Reduction of Maternal-Infant Transmission of Human Immunodeficiency Virus Type 1 with Zidovudine Treatment (3277 citations)
- Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 (2308 citations)
What are the main themes of his work throughout his whole career to date?
His scientific interests lie mostly in Internal medicine, Oncology, Breast cancer, Surgery and Chemotherapy.
His work in Tamoxifen, Cancer, Adjuvant therapy, Randomized controlled trial and Clinical trial are all subfields of Internal medicine research.
His Oncology research is multidisciplinary, relying on both Radiation therapy, Trastuzumab, Breast disease and Endocrine system.
He interconnects Gynecology, Cyclophosphamide and Hazard ratio in the investigation of issues within Breast cancer.
The various areas that he examines in his Surgery study include Pediatrics and Acute lymphocytic leukemia.
The concepts of his Chemotherapy study are interwoven with issues in Meta-analysis, Methotrexate and Mammary gland.
He most often published in these fields:
- Internal medicine (73.66%)
- Oncology (59.26%)
- Breast cancer (58.44%)
What were the highlights of his more recent work (between 2016-2021)?
- Internal medicine (73.66%)
- Breast cancer (58.44%)
- Oncology (59.26%)
In recent papers he was focusing on the following fields of study:
His primary areas of investigation include Internal medicine, Breast cancer, Oncology, Trastuzumab and Hazard ratio.
His research related to Chemotherapy, Randomized controlled trial, Adjuvant, Pertuzumab and Adjuvant therapy might be considered part of Internal medicine.
His Breast cancer research incorporates themes from Clinical trial and Randomization.
The Clinical trial study combines topics in areas such as Fertility and Surgery.
Richard D. Gelber has included themes like Early breast cancer, Survival rate, Meta-analysis, Endocrine system and Radiation therapy in his Oncology study.
In general Trastuzumab, his work in Lapatinib is often linked to In patient linking many areas of study.
Between 2016 and 2021, his most popular works were:
- Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer (515 citations)
- 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial (362 citations)
- 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial (362 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Breast cancer
Richard D. Gelber mostly deals with Internal medicine, Oncology, Breast cancer, Hazard ratio and Chemotherapy.
His study in Internal medicine concentrates on Randomized controlled trial and Meta-analysis.
His studies in Oncology integrate themes in fields like Pembrolizumab, Cancer, Radiation therapy and Trastuzumab.
Richard D. Gelber is interested in Tamoxifen, which is a branch of Breast cancer.
His work carried out in the field of Hazard ratio brings together such families of science as Chemotherapy regimen, Estrogen receptor and Cumulative incidence.
His study explores the link between Chemotherapy and topics such as Randomization that cross with problems in Propensity score matching, Adjuvant therapy and Aromatase inhibitor.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
